Brief: Piramal Pharma Approves Exercise Of Call Option For Acquisition Of Additional 41% Equity In Yapan Bio
10/08/2026 13:36
BRIEF-Piramal Pharma Approves Exercise Of Call Option For Acquisition Of Additional 41% Equity In Yapan Bio Aug 10 (Reuters) - Piramal Pharma Ltd (Mumbai) PIRM.NS:
APPROVED EXERCISE OF CALL OPTION FOR ACQUISITION OF ADDITIONAL 41% EQUITY IN YAPAN BIO
FINAL TERMS OF THE ACQUISITION ARE YET TO BE FINALIZED
Source text:
Further company coverage: PIRM.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Piramal Pharma (Mumbai)
See all newsBrief: Piramal Pharma (Mumbai) Says Commercial Arrangement With Bayer Pharmaceuticals To Expire On December 31, 2026
Brief: Piramal Pharma (Mumbai) Says Tax Authority Confirms Demand Of 40.6 Million Rupees And Imposes Equivalent Penalty
India's Piramal Pharma falls after US FDA observations at UK facility
Brief: Piramal Pharma Says US FDA Issues Form-483 With 7 Observations To Morpeth UK Facility
Brief: Piramal Pharma Approves Exercise Of Call Option For Acquisition Of Additional 41% Equity In Yapan Bio